Department of Surgical Oncology, Dr. BRA-IRCH, All India Institute of Medical Sciences, New Delhi, India.
Department of Radiation Oncology, Dr. BRA-IRCH, All India Institute of Medical Sciences, New Delhi, India.
J Egypt Natl Canc Inst. 2020 Jan 14;32(1):4. doi: 10.1186/s43046-019-0015-y.
This study aims to analyze risk factors, clinical profiles, treatment protocols, and disease outcomes in histologically proven resectable vulvar cancer (VC) patients according to tumor stage. This is a retrospective analysis of a prospectively collected database of 20 VC patients from May 2014 to June 2019.
The mean age of VC diagnosis was 55 years, with a range of 38-84 years. The incidence was four cases per year. The disease incidence was significantly more in post-menopausal (65%) and multiparous (90%) women. According to FIGO staging of vulvar cancer, stages I, II, and III were assigned to 6, 1, and 11 patients respectively. Two patients suffered from stage IVa vulvar melanoma. All patients had undergone surgical interventions. Patients treated with only nonsurgical (chemotherapy/radiotherapy/chemo-radiotherapy) treatment modalities were excluded from the study. Fifteen patients were treated with wide local excision (WLE), bilateral inguinofemoral dissection (B/L IFLND), and primary repair. Four and one patients were treated with radical vulvectomy (RV) and modified radical vulvectomy (MRV) [with or without B/L IFLND and PLND] respectively. Reconstruction with V-Y gracilis myocutaneous and local rotation advancement V-Y fasciocutaneous flaps were done in two patients. Therapeutic groin nodal dissection was performed in 19 patients except in one patient who was treated by palliative radical vulvectomy. In the final histopathology reports, tumor size varies from 0.5 to 6.5 cm (mean 3.35 cm) with the predominance of squamous cell carcinoma (18 out of 20 patients). Only 10 out of 18 eligible patients received adjuvant treatment. Poor patient compliance has been one of the major reasons for adjuvant treatment attrition rate. Systemic and loco-regional metastasis occurred in 3 patients each arm respectively. Poor follow up of patients is the key limitation of our study.
Vulvar cancer incidence was significantly high in post-menopausal and multiparous women. The most important prognostic factors were tumor stage and lymph node status. Oncological resection should be equated with functional outcome. The multidisciplinary team approach should be sought for this rare gynecological malignancy.
本研究旨在根据肿瘤分期分析组织学证实可切除外阴癌(VC)患者的风险因素、临床特征、治疗方案和疾病结局。这是对 2014 年 5 月至 2019 年 6 月期间前瞻性收集的 20 例 VC 患者数据库进行的回顾性分析。
VC 诊断的平均年龄为 55 岁,范围为 38-84 岁。每年发病 4 例。绝经后(65%)和多产妇(90%)女性的发病率明显更高。根据外阴癌FIGO 分期,Ⅰ期、Ⅱ期和Ⅲ期分别分配给 6、1 和 11 例患者。2 例患者患有Ⅳa 期外阴黑色素瘤。所有患者均接受了手术干预。仅接受非手术(化疗/放疗/化放疗)治疗的患者被排除在研究之外。15 例患者接受了广泛局部切除术(WLE)、双侧腹股沟股部解剖术(B/L IFLND)和原发性修复术。4 例和 1 例患者分别接受根治性外阴切除术(RV)和改良根治性外阴切除术(MRV)[伴或不伴 B/L IFLND 和 PLND]。2 例患者采用 V-Y 股薄肌肌皮瓣和局部旋转推进 V-Y 筋膜皮瓣进行重建。19 例患者进行了治疗性腹股沟淋巴结清扫术,除 1 例姑息性根治性外阴切除术患者外。在最终的组织病理学报告中,肿瘤大小从 0.5 到 6.5cm(平均 3.35cm)不等,以鳞状细胞癌为主(20 例患者中有 18 例)。只有 18 例合格患者中的 10 例接受了辅助治疗。患者依从性差是辅助治疗失败的主要原因之一。全身和局部区域转移分别发生在 3 例患者中。患者随访不良是我们研究的关键限制。
绝经后和多产妇的 VC 发病率明显较高。最重要的预后因素是肿瘤分期和淋巴结状态。应将肿瘤的根治性切除等同于功能结局。对于这种罕见的妇科恶性肿瘤,应寻求多学科团队的方法。